Important new research from Professor Chris Exley linking aluminium in vaccines with autism
- Thread starter currer
- Start date
pattismith
Senior Member
- Messages
- 3,988
"Serum aluminium > 30 μg/L in dialysis patients has been associated with osteomalacia and related disorders and > 80 μg/L associated with encephalopathy. Up to 5 mg/kg of desferrioxamine once or twice weekly has been shown to be safe and effective for long-term treatment of aluminium overload."
Hip
Senior Member
- Messages
- 18,244
It could be a red herring, but it's worth noting that no reliable study has ever been conducted comparing autism rates in vaccinated versus unvaccinated children (there was one recent study, but it was retracted due to methodological issues).
I wonder how patients with sudden onset ME/CFS appearing just days after a vaccination feel about this? I should think these patients would like to see more research into how vaccination may trigger disease.
pattismith
Senior Member
- Messages
- 3,988
This study allows some comparison with Ewley's one (especially brains aluminium concentrations in patients with different outcome)
Lancet. 1978 Apr 29;1(8070):901-4.
Brain-aluminium concentration in dialysis encephalopathy.
McDermott JR, Smith AI, Ward MK, Parkinson IS, Kerr DN.
Abstract
Brain-aluminium concentrations were found to be significantly higher in 7 patients dying with dialysis encephalopathy (mean 15.9 microgram aluminium/g dry weight) than in 11 dialysed controls (4.4 microgram/g) and in 2 uraemic patients who were not dialysed (2.7 microgram/g). The grey matter from the patients with dialysis encephalopathy contained about three times as much aluminium as white matter. The results suggest that dialysis with untreated and/or softened tap-water (aluminium concentration 0.1-1.2 mg/1) makes the major contribution to brain-aluminium levels; dialysis with deionised water (aluminium concentration normally less than 0.02 mg/1) and intake of phosphate-binding AL(OH)3 gel are less important. Brain aluminium levels remain elevated for up to four years after restoration of good renal function by transplantation. The association of dialysis encephalopathy with high levels of aluminium in the brain and in the dialysis water emphasises the potential neurotoxicity of aluminium in man.
Edit : this book is also very informative on the aluminium toxicity
Lancet. 1978 Apr 29;1(8070):901-4.
Brain-aluminium concentration in dialysis encephalopathy.
McDermott JR, Smith AI, Ward MK, Parkinson IS, Kerr DN.
Abstract
Brain-aluminium concentrations were found to be significantly higher in 7 patients dying with dialysis encephalopathy (mean 15.9 microgram aluminium/g dry weight) than in 11 dialysed controls (4.4 microgram/g) and in 2 uraemic patients who were not dialysed (2.7 microgram/g). The grey matter from the patients with dialysis encephalopathy contained about three times as much aluminium as white matter. The results suggest that dialysis with untreated and/or softened tap-water (aluminium concentration 0.1-1.2 mg/1) makes the major contribution to brain-aluminium levels; dialysis with deionised water (aluminium concentration normally less than 0.02 mg/1) and intake of phosphate-binding AL(OH)3 gel are less important. Brain aluminium levels remain elevated for up to four years after restoration of good renal function by transplantation. The association of dialysis encephalopathy with high levels of aluminium in the brain and in the dialysis water emphasises the potential neurotoxicity of aluminium in man.
Edit : this book is also very informative on the aluminium toxicity
Last edited:
The criticism du jour of Dr. Exley's work is that there are no healthy controls to compare the autism brains to. I'm including a response here from Dr. Exley onthis topic:
“Our measurements of Al in human tissue are the most respected anywhere and the reasons for this are our attention to all details and specifically extraneous contamination... Please see the Metallomics paper cited in our paper to provide a specifc response to this.
Our quantitative analyses on the brains of 5 individuals represent the ONLY donors available at the autism brain bank in the UK. We discussed control tissues but the only available were not age-matched and nor were they true controls as the donors were individuals in their 40s and 50s who died of a certain disease or condition. No age-matched healthy donor brain tissues were available. However, we have more data on the Al content of human brain tissue than anyone else and so we are in a position to compare our autism data with other data relating to almost 100 human brains. This is how we can come to our judgement that the values measured were some of the highest values ever measured in any individuals. No one questioned similar data published this time last year for familial AD.”
“Our measurements of Al in human tissue are the most respected anywhere and the reasons for this are our attention to all details and specifically extraneous contamination... Please see the Metallomics paper cited in our paper to provide a specifc response to this.
Our quantitative analyses on the brains of 5 individuals represent the ONLY donors available at the autism brain bank in the UK. We discussed control tissues but the only available were not age-matched and nor were they true controls as the donors were individuals in their 40s and 50s who died of a certain disease or condition. No age-matched healthy donor brain tissues were available. However, we have more data on the Al content of human brain tissue than anyone else and so we are in a position to compare our autism data with other data relating to almost 100 human brains. This is how we can come to our judgement that the values measured were some of the highest values ever measured in any individuals. No one questioned similar data published this time last year for familial AD.”
I suppose one difference between antacids and vaccines is the rate at which aluminum enters the bloodstream, e.g. from your link a vaccine at 0.45mg injected over a couple of seconds versus an antacid at 0.2% of 600mg over a couple of hours. The vaccine gets aluminum into the bloodstream about 1000 times faster, and presumably concentration levels/gradients are about 1000 times higher for some time.
I don't know how long it takes to clear aluminum from the blood, which would need to be factored in.
Maybe the 0.2% absorption rate you quote is wrong, because if that is true, and the aluminum dose in vaccines is considered safe, wouldn't that imply that taking 1000 antacids in one dose is also safe (with respect to aluminum)?
Hip
Senior Member
- Messages
- 18,244
The local concentration levels/gradients where the aluminum compound was injected would momentarily be 1000s of times higher, but I would think that within minutes, that aluminum would get distributed and diluted throughout the whole bloodstream and the extracellular fluids, and then be no different to orally ingested aluminum in terms of concentration.
So if there are adverse effects from such high local concentrations, those effects would have to take place rapidly, before the aluminum gets dispersed.
I go more for the idea that microparticles or nanoparticles of aluminum compounds might be the culprit, with this particles being phagocytized by immune cells and carried to places such as the lymph nodes.
That 0.2% figure comes from this book, which says:
Sounds like a fairly reliable figure.
Jonathan Edwards
"Gibberish"
- Messages
- 5,256
The whole point of using alum as an adjuvant is that it stays put in the muscle where the IM injection is until it is taken up by macrophages several hours later and gradually transferred to lymph nodes a day or so later maybe. None of it is intended to go in to the bloodstream. The proportion getting any further than the local lymph nodes is likely to be tiny. Any that does is likely to embolism in the lung. The chances of any getting to the brain must be very small indeed.
Hip
Senior Member
- Messages
- 18,244
OK, that makes sense. I forgot that aluminum hydroxide is insoluble in water, which would make it tend to stay put in the muscle.
*The whole point of using alum as an adjuvant is that it stays put in the muscle where the IM injection is until it is taken up by macrophages several hours later and gradually transferred to lymph nodes a day or so later maybe. None of it is intended to go in to the bloodstream. The proportion getting any further than the local lymph nodes is likely to be tiny. Any that does is likely to embolism in the lung. The chances of any getting to the brain must be very small indeed.*
The following paper makes it clear that this is a misconception.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318414/
Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
Romain Kroum Gherardi,1,* Housam Eidi,1 Guillemette Crépeaux,1 François Jerome Authier,1 and Josette Cadusseau1
Abstract
Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunological adjuvant of vaccines. Concerns linked to the use of alum particles emerged following recognition of their causative role in the so-called macrophagic myofasciitis (MMF) lesion detected in patients with myalgic encephalomyelitis/chronic fatigue/syndrome. MMF revealed an unexpectedly long-lasting biopersistence of alum within immune cells in presumably susceptible individuals, stressing the previous fundamental misconception of its biodisposition. We previously showed that poorly biodegradable aluminum-coated particles injected into muscle are promptly phagocytosed in muscle and the draining lymph nodes, and can disseminate within phagocytic cells throughout the body and slowly accumulate in brain. This strongly suggests that long-term adjuvant biopersistence within phagocytic cells is a prerequisite for slow brain translocation and delayed neurotoxicity. The understanding of basic mechanisms of particle biopersistence and brain translocation represents a major health challenge, since it could help to define susceptibility factors to develop chronic neurotoxic damage. Biopersistence of alum may be linked to its lysosome-destabilizing effect, which is likely due to direct crystal-induced rupture of phagolysosomal membranes. Macrophages that continuously perceive foreign particles in their cytosol will likely reiterate, with variable interindividual efficiency, a dedicated form of autophagy (xenophagy) until they dispose of alien materials. Successful compartmentalization of particles within double membrane autophagosomes and subsequent fusion with repaired and re-acidified lysosomes will expose alum to lysosomal acidic pH, the sole factor that can solubilize alum particles. Brain translocation of alum particles is linked to a Trojan horse mechanism previously described for infectious particles (HIV, HCV), that obeys to CCL2, signaling the major inflammatory monocyte chemoattractant.
Billions of humans have been vaccinated and marked regression or eradication of several severe infectious diseases was observed. Nowadays, the potential applications of vaccines extend far beyond prevention of infectious diseases, and vaccination is considered to be a most promising weapon against a variety of different conditions. Vaccine safety has been regarded as excellent at the level of the population (1), but adverse effects have also been reported (2).
Concerns about the use of aluminum adjuvants have emerged following (i) recognition of their role at the origin of the so-called macrophagic myofasciitis (MMF) lesion in 2001 (3, 4), which revealed fundamental misconception of their adjuvant effect and pointed out their unexpectedly long-lasting biopersistence (4); and (ii) demonstration of their apparent capacity to migrate in lymphoid organs and then disseminate throughout the body within monocyte-lineage cells and progressively accumulate in the brain (5).
The present paper will review these emerging characteristics of alum adjuvant particles that raise concerns about innocuity of this widely used compound.
The following paper makes it clear that this is a misconception.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318414/
Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
Romain Kroum Gherardi,1,* Housam Eidi,1 Guillemette Crépeaux,1 François Jerome Authier,1 and Josette Cadusseau1
Abstract
Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunological adjuvant of vaccines. Concerns linked to the use of alum particles emerged following recognition of their causative role in the so-called macrophagic myofasciitis (MMF) lesion detected in patients with myalgic encephalomyelitis/chronic fatigue/syndrome. MMF revealed an unexpectedly long-lasting biopersistence of alum within immune cells in presumably susceptible individuals, stressing the previous fundamental misconception of its biodisposition. We previously showed that poorly biodegradable aluminum-coated particles injected into muscle are promptly phagocytosed in muscle and the draining lymph nodes, and can disseminate within phagocytic cells throughout the body and slowly accumulate in brain. This strongly suggests that long-term adjuvant biopersistence within phagocytic cells is a prerequisite for slow brain translocation and delayed neurotoxicity. The understanding of basic mechanisms of particle biopersistence and brain translocation represents a major health challenge, since it could help to define susceptibility factors to develop chronic neurotoxic damage. Biopersistence of alum may be linked to its lysosome-destabilizing effect, which is likely due to direct crystal-induced rupture of phagolysosomal membranes. Macrophages that continuously perceive foreign particles in their cytosol will likely reiterate, with variable interindividual efficiency, a dedicated form of autophagy (xenophagy) until they dispose of alien materials. Successful compartmentalization of particles within double membrane autophagosomes and subsequent fusion with repaired and re-acidified lysosomes will expose alum to lysosomal acidic pH, the sole factor that can solubilize alum particles. Brain translocation of alum particles is linked to a Trojan horse mechanism previously described for infectious particles (HIV, HCV), that obeys to CCL2, signaling the major inflammatory monocyte chemoattractant.
Billions of humans have been vaccinated and marked regression or eradication of several severe infectious diseases was observed. Nowadays, the potential applications of vaccines extend far beyond prevention of infectious diseases, and vaccination is considered to be a most promising weapon against a variety of different conditions. Vaccine safety has been regarded as excellent at the level of the population (1), but adverse effects have also been reported (2).
Concerns about the use of aluminum adjuvants have emerged following (i) recognition of their role at the origin of the so-called macrophagic myofasciitis (MMF) lesion in 2001 (3, 4), which revealed fundamental misconception of their adjuvant effect and pointed out their unexpectedly long-lasting biopersistence (4); and (ii) demonstration of their apparent capacity to migrate in lymphoid organs and then disseminate throughout the body within monocyte-lineage cells and progressively accumulate in the brain (5).
The present paper will review these emerging characteristics of alum adjuvant particles that raise concerns about innocuity of this widely used compound.
Autism is vaccine injury.
HowToEscape?
Senior Member
- Messages
- 626
That’s an insult to all of the people who were born with autism before vaccines.
Hip, you might find this presentation interesting as it addresses your question on how aluminum can reach the brain:
https://www.youtube.com/watch?time_continue=31&v=ICQD9wuQmSc
To summarize as best I can:
In some people, muscle biopsies at the site of vaccination show aluminum is retained there in lesions typically 5 years after the time of vaccination. Some people therefore cannot properly remove aluminum from their bodies.
In mouse studies of this, some mouse species show more aluminum persistence at the site of injection, indicating this might be a genetic effect.
Aluminum nanoparticles can remain in phagocytes for long periods of time, where they spread around the body and slowly build up in the brain via a 'Trojan horse' mechanism similar to the way in which HIV enters the brain.